Lupus Clinical Trials

A listing of Lupus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 254 clinical trials
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

(SLE) and cutaneous lupus erythematosus (CLE; subacute cutaneous lupus erythematosus [SCLE] and/or discoid lupus erythematosus [DLE]) participants in a randomized, double-blind, placebo-controlled

estrogen
lupus
cutaneous lupus
corticosteroids
  • 0 views
  • 11 Aug, 2022
  • 31 locations
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus (ALLEGORY)

This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus

rheumatism
lupus
antimalarials
  • 67 views
  • 25 Jul, 2022
  • 59 locations
A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

The main purpose of this study is to assess the efficacy and safety of LY3361237 in participants with at least moderately active systemic lupus erythematosus (SLE). Study will last up to 34

rheumatism
lupus
  • 0 views
  • 29 Jul, 2022
  • 33 locations
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

without systemic lupus erythematosus (SLE) that is not well controlled with standard of care therapy.

  • 10 views
  • 23 Jul, 2022
  • 27 locations
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus

This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mosunetuzumab in participants with systemic lupus erythematosus (SLE).

mycophenolate
rheumatism
lupus
corticosteroids
  • 0 views
  • 27 Jul, 2022
  • 5 locations
Study of M5049 in CLE and SLE Participants

This study is to evaluate the safety, tolerability and pharmacokinetics (PK) of orally administered M5049 in participants with systemic lupus erythematosus (SLE) or cutaneous lupus erythematosus

lupus
cutaneous lupus
  • 4 views
  • 21 Jul, 2022
  • 10 locations
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO)

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

lupus
immunosuppressive agents
corticosteroids
sjogren's syndrome
rheumatism
  • 202 views
  • 25 Jul, 2022
  • 220 locations
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

The purpose of this study is to evaluate the safety and effectiveness of treatment with branebrutinib treatment in participants with active systemic Lupus Erythematosus (SLE) or Primary

abatacept
lupus
sjogren's syndrome
arthritis
progressive systemic sclerosis
  • 399 views
  • 11 Aug, 2022
  • 66 locations
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis (IRIS)

The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis

anifrolumab
chronic kidney disease
nephritis
  • 7 views
  • 11 Jul, 2022
  • 18 locations
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (SANCTUARY)

The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and demonstrate proof-of-concept of the efficacy of terminal complement inhibition in participants with LN (LN Cohort) or IgAN (IgAN Cohort).

immunoglobulin a
immunosuppression
nephritis
lupus
proteinuria
  • 5 views
  • 22 Jul, 2022
  • 68 locations